Gossamer Bio Statistics
Total Valuation
Gossamer Bio has a market cap or net worth of $82.86 million. The enterprise value is $186.58 million.
| Market Cap | 82.86M |
| Enterprise Value | 186.58M |
Important Dates
The next estimated earnings date is Friday, August 7, 2026, after market close.
| Earnings Date | Aug 7, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Gossamer Bio has 488.85 million shares outstanding. The number of shares has increased by 1.70% in one year.
| Current Share Class | 488.85M |
| Shares Outstanding | 488.85M |
| Shares Change (YoY) | +1.70% |
| Shares Change (QoQ) | +3.32% |
| Owned by Insiders (%) | 1.54% |
| Owned by Institutions (%) | 31.61% |
| Float | 288.22M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 1.49 |
| Forward PS | 5.37 |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 3.36 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.20
| Current Ratio | 2.20 |
| Quick Ratio | 1.92 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -3.52 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -52.29% |
| Return on Invested Capital (ROIC) | -89.98% |
| Return on Capital Employed (ROCE) | -53.55% |
| Weighted Average Cost of Capital (WACC) | 7.53% |
| Revenue Per Employee | $342,821 |
| Profits Per Employee | -$1.11M |
| Employee Count | 162 |
| Asset Turnover | 0.27 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -88,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -91.85% in the last 52 weeks. The beta is 2.04, so Gossamer Bio's price volatility has been higher than the market average.
| Beta (5Y) | 2.04 |
| 52-Week Price Change | -91.85% |
| 50-Day Moving Average | 0.18 |
| 200-Day Moving Average | 1.39 |
| Relative Strength Index (RSI) | 48.48 |
| Average Volume (20 Days) | 42,730,777 |
Short Selling Information
The latest short interest is 73.18 million, so 14.97% of the outstanding shares have been sold short.
| Short Interest | 73.18M |
| Short Previous Month | 53.70M |
| Short % of Shares Out | 14.97% |
| Short % of Float | 25.39% |
| Short Ratio (days to cover) | 4.03 |
Income Statement
In the last 12 months, Gossamer Bio had revenue of $55.54 million and -$180.40 million in losses. Loss per share was -$0.78.
| Revenue | 55.54M |
| Gross Profit | 55.54M |
| Operating Income | -171.31M |
| Pretax Income | -180.48M |
| Net Income | -180.40M |
| EBITDA | -37.87M |
| EBIT | -38.77M |
| Loss Per Share | -$0.78 |
Balance Sheet
The company has $99.22 million in cash and $202.93 million in debt, with a net cash position of -$103.72 million or -$0.21 per share.
| Cash & Cash Equivalents | 99.22M |
| Total Debt | 202.93M |
| Net Cash | -103.72M |
| Net Cash Per Share | -$0.21 |
| Equity (Book Value) | -161.48M |
| Book Value Per Share | -0.69 |
| Working Capital | 68.03M |
Cash Flow
In the last 12 months, operating cash flow was -$170.26 million and capital expenditures -$53,000, giving a free cash flow of -$170.32 million.
| Operating Cash Flow | -170.26M |
| Capital Expenditures | -53,000 |
| Depreciation & Amortization | 23,000 |
| Net Borrowing | n/a |
| Free Cash Flow | -170.32M |
| FCF Per Share | -$0.35 |
Margins
| Gross Margin | 100.00% |
| Operating Margin | -308.46% |
| Pretax Margin | -324.98% |
| Profit Margin | n/a |
| EBITDA Margin | -68.19% |
| EBIT Margin | -69.80% |
| FCF Margin | n/a |
Dividends & Yields
Gossamer Bio does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -1.70% |
| Shareholder Yield | -1.70% |
| Earnings Yield | -217.71% |
| FCF Yield | -205.55% |
Analyst Forecast
The average price target for Gossamer Bio is $3.86, which is 2,177.29% higher than the current price. The consensus rating is "Buy".
| Price Target | $3.86 |
| Price Target Difference | 2,177.29% |
| Analyst Consensus | Buy |
| Analyst Count | 7 |
| Revenue Growth Forecast (3Y) | 39.79% |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Gossamer Bio has an Altman Z-Score of -18.54 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -18.54 |
| Piotroski F-Score | 1 |